Federal officials hope the pediatric dose can help close a major gap in the nation’s vaccine campaign that has worried parents, educators and public health leaders.
Author: Sharon LaFraniere and Noah Weiland
F.D.A. Says Pfizer Vaccine’s Benefits Outweigh Key Risks in Children 5 to 11
The findings could add momentum for F.D.A. authorization of the pediatric dose, perhaps as early as next week, a long-awaited development that would affect 28 million children.
F.D.A. to Allow ‘Mix and Match’ Approach for Covid Booster Shots
The agency may act this week, when it is expected to authorize booster shots for recipients of the Moderna and Johnson & Johnson vaccines.
F.D.A. Panel Recommends Moderna Booster for Certain Groups
Those eligible for the extra shot would include adults over 65 and others at high risk — the same groups now eligible for a Pfizer-BioNTech boost
Pfizer Asks F.D.A. to Authorize Its Covid-19 Vaccine for Children 5 to 11
The agency has promised to move quickly on the request and has tentatively scheduled a meeting at the end of the month to consider it.
U.S. Booster Policy Is in Flux as Studies Add to Dissent
A week before President Biden’s plan is to roll out, scientists are at odds about whether extra coronavirus shots are needed and for whom.